TLRY

Current Thesis

The cannabis Schedule-III reform trade is back on the table heading into the DEA's expedited adult-use rescheduling hearing (begins 2026-06-29, concludes ≤2026-07-15). The sector is re-accelerating (Motley Fool flagged cannabis "heating up again" 2026-06-01; MSOs Trulieve/Curaleaf/GTI posted strong Q1 on 280E relief) — but TLRY's own chart is busted: ~$5.12 (2026-06-03), below the 200-day SMA, near the bottom of a $3.51–$23.20 52-week range after fully round-tripping the late-2025/April-2026 reform spike. This is a defined-risk binary-catalyst probe into June 29, NOT a trend-following entry. The structure is wrong for momentum; the only edge is betting the hearing re-ignites the whole complex.

Bull Case

• DEA expedited hearing on BROADER (adult-use) Schedule III rescheduling begins 2026-06-29 9am ET (Arlington VA), the first hard regulatory date in years that could legalize the economics of the state-licensed rec market (currently still Schedule I). (Federal Register / DEA notice)
• Partial rescheduling already LANDED 2026-04-23: DOJ moved FDA-approved drugs + state-medical marijuana to Schedule III — proof the administration is executing, not just talking. (DOJ OPA, 2026-04-23)
• Q3 FY2026 (reported ~2026-04-01) was a RECORD: net revenue $206.7M, +11% YoY (11% organic), gross profit $55M +6% YoY, and a surprise adjusted profit of +$0.02/sh — ending the "perpetual loss" narrative. (Globe & Mail / BNN press release)
• International cannabis +70% YoY (Germany legalization), best quarterly international cannabis revenue in company history; cannabis segment $64.8M = 31% of revenue. (Q3 FY2026 call)
• BrewDog acquisition pushes Tilray to ~$1.2B annualized revenue — a diversified beverage + cannabis platform, not a zombie LP. (Q3 FY2026)
• Sector cluster confirming: Canopy (CGC) reports FY2026 2026-06-15; MSOs posting profitable Q1 — peers firming ahead of the hearing. (Investorideas, 2026-05-13)

Bear Case

• The chart is a value-trap textbook: below the 200-day SMA, near a 52-week low of $3.51, ChartMill technical rating 0/10, sell signal on both timeframes (2026-06). Momentum books do NOT initiate below the 200d into a downtrend.
• "Rescheduling will finally happen" is the most-burned trade since 2022; the stock went $5→$23→$5, so every reform long who chased the spike is underwater — overhead supply at every level.
• The 2026-04-23 partial rescheduling was a textbook sell-the-news; the 2026-06-29 hearing carries the same buy-the-rumor/sell-the-fact risk, and it only CONCLUDES (≤2026-07-15) with a recommendation, not a final rule — slow and litigable.
• Recreational cannabis explicitly REMAINS Schedule I unless the broader hearing changes it; a "no rec rescheduling" or punt-to-litigation outcome guts the TLRY-specific thesis. (Foley & Lardner, 2026-04)
• Still GAAP loss-making: FY2026 EPS consensus ~-$0.61 on ~$867M revenue; the "surprise profit" was adjusted, not GAAP.
• TLRY is increasingly a CRAFT-BEER company post-BrewDog — the reform catalyst now moves a shrinking ~31%-of-revenue cannabis slice, diluting the reform beta.

Setup & Price Structure

• Last ~$5.12 (2026-06-03); prior close ~$5.40 (2026-06-02); 2026-06-03 intraday range $5.11–$5.38.
• 52-week range $3.51–$23.20 — currently ~bottom 8% of range; full round-trip of the reform spike.
• Below 200-day SMA; short- and long-term trend both negative (ChartMill 0/10, 2026-06).
• Read: basing/busted name, no clean higher-low sequence yet. A momentum entry requires reclaiming and holding a near-term level (daily close back above ~$5.80–$6.00 on sector-wide expansion). Chasing $5 here on hope is catalyst-gambling, not trend-riding.
• Sizing frame: archetype-5 binary. If played, LOW probe only, defined risk into June 29, hard stop on a daily close below ~$4.50.

Catalyst Calendar (next 30 days)

• 2026-06-15: Canopy Growth (CGC) FY2026 results before open — direct peer read-through, sector sentiment proxy.
• 2026-06-22: DEA notifies selected hearing participants — headline/sentiment trigger.
• 2026-06-29: DEA expedited adult-use Schedule III hearing BEGINS, 9am ET, Arlington VA — THE binary. (concludes ≤2026-07-15)
• ~2026-07-15 (just outside window): hearing concludes; recommendation expected.
• 2026-07-29 (outside window, confirmed): TLRY Q4/FY2026 earnings, after close — EARNINGS BLACKOUT begins ~3 trading days prior.
• 2026-05-29: Marijuana Moment review on cannabis anti-tumor effects — science-PR, NOT a tradeable catalyst (noise).

What Would Change Our Mind

• TO BUY (momentum confirm): daily close back above ~$5.80–$6.00 with MSOS/sector expanding and TLRY reclaiming the 50-day — converts catalyst-gamble into a real trend entry.
• TO SIZE UP: hearing (2026-06-29→07-15) produces a clear adult-use Schedule III recommendation → rec economics legalize, re-rate the whole complex.
• TO KILL THE TRADE: daily close below ~$4.50 (loss of pre-hearing base) OR hearing concludes with no adult-use rescheduling / a punt to litigation → sell immediately (the sell-the-news outcome).
• NO-AVERAGE-DOWN reminder: this is the canonical cannabis-reform value trap. If stopped, do NOT re-buy lower — wait for a fresh higher-low setup.

Correlation Notes

• Trades as cannabis-reform beta: tightly correlated to MSOS, CGC, Curaleaf, Green Thumb, Trulieve. The 2026-06-29 DEA hearing is a SECTOR catalyst — a TLRY position is effectively a leveraged sector bet; do not double up with another cannabis name (correlated risk).
• Increasingly cross-correlated to consumer-beverage/craft-beer demand post-BrewDog (~$1.2B annualized), which softens pure-reform beta.
• Germany/EU medical-cannabis legalization is a secondary, independent driver (international +70% YoY) — the one genuinely accelerating leg regardless of US reform.